NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) breached their fiduciary duties to shareholders. If you currently own Amylyx stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about. ...

Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) is one of billionaire Steve Cohen’s small-cap stock picks with huge upside potential. On October 3, Bank of America Securities raised the stock’s price target to $16 from $14 while maintaining a ‘Buy’ rating. BofA Securities Lifts Amylyx Pharmaceuticals Inc. (AMLX) Price Target Amid Bolstered Balance Sheet The price target hike comes on the heels of Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) raising $175 million on the issuance of 17.5 million shares. Net proceeds ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Whil ...

Shares of Amylyx Pharmaceuticals, Inc. (AMLX) have gained 3.6% over the past four weeks to close the last trading session at $14.31, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $18.5 indicates a potential upside of 29.3%.The mean estimate comprises eight short-term price targets with a standard deviation of $3.85. While the lowest estimate of $12.00 indicates a 16.1% decline ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Amylyx Pharmaceuticals, Inc. (AMLX) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.Amylyx Pharmaceuticals, Inc. is one of 955 individual stocks in the Medical sector. Collectively, these companies sit at #4 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by ...

Company Overview - Amylyx Pharmaceuticals, Inc. (AMLX) is currently positioned as an intriguing investment choice due to solid earnings estimate revisions and a favorable Zacks Industry Rank [1][3]. Industry Position - The Medical – Drugs industry, where Amylyx operates, has a Zacks Industry Rank of 68 out of more than 250 industries, indicating a strong position relative to other segments [2]. - The industry is experiencing broad trends that are positively impacting securities across the board, suggesting a rising tide effect [2]. Earnings Estimates - Over the past month, earnings estimates for Amylyx have improved, with current quarter estimates rising from a loss of $0.45 per share to a loss of $0.44 per share, and current year estimates increasing from a loss of $1.74 per share to a loss of $1.58 per share [4]. - These revisions reflect a more bullish outlook from analysts regarding the company's short and long-term prospects [3][4]. Investment Recommendation - Given the strong industry performance and positive estimate revisions, Amylyx is recommended as a potential investment for those seeking opportunities in a robust industry segment [5].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Amylyx Pharmaceuticals, Inc. due to allegations of misleading statements regarding the commercial launch of their drug Relyvrio, which may have breached fiduciary duties to shareholders [2][3]. Group 1: Investigation Details - A class action complaint was filed against Amylyx on July 1, 2025, covering a class period from November 11, 2022, to November 8, 2023 [2]. - The complaint alleges that the board of directors made false and misleading statements about the success of the Relyvrio launch, including claims of "significant demand" that were not substantiated [3]. - Specific allegations include that the initial surge in demand for Relyvrio was temporary and that there was no meaningful growth potential among newly diagnosed ALS patients [3]. Group 2: Implications of Allegations - The complaint states that high discontinuation rates of Relyvrio were not disclosed, which undermined the drug's commercial viability and inflated the perceived potential for acquiring new patients [3]. - As a result of these misleading statements, the company's public disclosures were deemed materially false and lacked a reasonable basis [3]. Group 3: Next Steps for Shareholders - Long-term stockholders of Amylyx are encouraged to contact Bragar Eagel & Squire for more information regarding their rights and potential claims [4].

Core Insights - Multiple biotech companies are experiencing significant stock price increases, reaching new 52-week highs due to clinical advancements, regulatory milestones, and strategic funding initiatives [1] Company Summaries Amylyx Pharmaceuticals Inc. (AMLX) - On September 10, 2025, Amylyx reached a new 52-week high of $12.25, a substantial increase from its previous low of $2.47 [2] - The company announced a $175 million underwritten public offering of common stock, consisting of 17.5 million shares priced at $10.00 each, with an option for underwriters to purchase an additional 2.625 million shares [3] - Proceeds from the offering will support the commercial launch of avexitide, currently in Phase 3 trials, and fund ongoing research and development, general corporate purposes, and working capital [3] - Despite discontinuing the ORION program for AMX0035 due to disappointing results, Amylyx continues to advance other candidates, including AMX0035 for Wolfram syndrome and AMX0114 for ALS [4] Amneal Pharmaceuticals Inc. (AMRX) - On September 10, 2025, Amneal's stock reached a new 52-week high of $9.97 during intraday trading, closing at $9.82, reflecting a slight decline of 0.71% from the previous close [4][5] - The stock's performance is supported by the approval of its risperidone extended-release injectable suspension, enhancing its central nervous system portfolio [5] - Amneal is awaiting FDA decisions on biosimilar candidates for denosumab, with potential regulatory approval expected later in 2025, which could significantly boost revenue [6] - The company is also expanding its specialty portfolio with the rollout of Brekiya and the adoption of CREXONT, alongside a collaboration with Metsera to develop GLP-1 therapies [6] argenx SE (ARGX) - On September 10, 2025, argenx reached a new 52-week high of $779.03, closing slightly lower at $762.89, reflecting a modest intraday decline of 0.54% [7] - The increase in share price follows positive topline results from the ADAPT-SERON trial for VYVGART in seronegative generalized myasthenia gravis, which met its primary endpoint [8] - The successful trial positions argenx to pursue FDA label expansion for VYVGART, potentially broadening its market reach and revenue [8][9] - Upcoming milestones include an R&D spotlight webinar on ARGX-119 and expected label expansion decisions for VYVGART-SC in Japan and Canada by year-end [10]

Summary of Amylyx Pharmaceuticals FY Conference Call Company Overview - **Company**: Amylyx Pharmaceuticals (NasdaqGS:AMLX) - **Focus**: Clinical-stage biotech developing therapies for neurodegenerative and endocrine diseases [1][2] Key Programs and Developments - **Avexitide**: - Late-stage asset focused on post-bariatric hypoglycemia (PBH) - Phase 3 LUCIDITY study ongoing, with expected enrollment completion by the end of 2025 and data release in the first half of 2026 [3][20] - First-in-class GLP-1 receptor antagonist with FDA Breakthrough Therapy Designation for PBH [5][6] - Mechanism: Blocks GLP-1 to reduce insulin production, addressing hypoglycemia caused by hyperinsulinemia [6][8] - Phase 2 studies showed a 64% reduction in level 3 hypoglycemic events and a 53% reduction in level 2 events [13][14] - Safety profile: Generally well tolerated with mild to moderate side effects [15] - **Wolfram Syndrome**: - Rare, progressive disease with no current treatment - Using AMX0035, showing positive outcomes in C-peptide and HbA1c levels [21][24] - Estimated 3,000 to 3,500 patients in the U.S. [25] - **ALS Program**: - Targeting axonal degeneration with AMX0114, an antisense oligonucleotide aimed at Calpain 2 - First patient data expected by the end of 2025 [26] Financial Position - Recently completed financing of $175 million, extending runway into 2027 - Cash balance of $180 million as of June 30, 2025 [27] Market Opportunity - Over 160,000 individuals in the U.S. suffer from persistent hypoglycemia post-bariatric surgery, a significant unmet medical need [18][20] - Over 2 million bariatric surgeries performed in the U.S. over the last decade, with 8% developing PBH [18] Regulatory and Patent Status - Patent rights for avexitide extend through 2037, with orphan designation granted for PBH [20][21] Conclusion - Amylyx Pharmaceuticals is actively advancing multiple programs in rare diseases with significant unmet needs, backed by a strong financial position and promising clinical data [27]

Core Viewpoint - Amylyx Pharmaceuticals, Inc. has announced a public offering of 17,500,000 shares of its common stock at a price of $10.00 per share, with an additional option for underwriters to purchase up to 2,625,000 shares [1] Company Summary - The public offering consists entirely of shares offered by Amylyx Pharmaceuticals [1] - The company has granted underwriters a 30-day option to purchase additional shares at the public offering price [1]